Similar articles

• Caspofungin versus liposomal amphotericin B for empirical therapy.

  Schneemann M, Imhof A. Schneemann M, et al. N Engl J Med. 2005 Jan 27;352(4):410-4; author reply 410-4. N Engl J Med. 2005. PMID: 15675094 No abstract available.
• Caspofungin versus liposomal amphotericin B for empirical therapy.

  Tattevin P, Bareau B, Camus C. Tattevin P, et al. N Engl J Med. 2005 Jan 27;352(4):410-4; author reply 410-4. N Engl J Med. 2005. PMID: 15675091 No abstract available.
• Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?

  Klastersky J. Klastersky J. N Engl J Med. 2004 Sep 30;351(14):1445-7. doi: 10.1056/NEJMe048203. N Engl J Med. 2004. PMID: 15459307 No abstract available.
• Use of newer antifungal therapies in clinical practice: what do the data tell us?

  Perfect JR. Perfect JR. Oncology (Williston Park). 2004 Nov;18(13 Suppl 7):15-23. Oncology (Williston Park). 2004. PMID: 15651178 Review.
• [Update on therapy of invasive mycoses in hematology and oncology].

  Maschmeyer G, Haas A, Böhme A. Maschmeyer G, et al. Dtsch Med Wochenschr. 2005 Jun 3;130(22):1381-4. doi: 10.1055/s-2005-868738. Dtsch Med Wochenschr. 2005. PMID: 15915381 Review. German. No abstract available.